Logo image of NVO

NOVO-NORDISK A/S-SPONS ADR (NVO) Stock Overview

NYSE:NVO - US6701002056 - ADR

56.46 USD
+0.35 (+0.62%)
Last: 8/29/2025, 8:04:00 PM
56.44 USD
-0.02 (-0.04%)
After Hours: 8/29/2025, 8:04:00 PM

NVO Key Statistics, Chart & Performance

Key Statistics
52 Week High138.62
52 Week Low45.05
Market Cap250.88B
Shares4.44B
Float4.18B
Yearly Dividend1.55
Dividend Yield3.25%
EPS(TTM)3.9
PE14.48
Fwd PE13.08
Earnings (Next)11-05 2025-11-05/bmo
IPO05-17 1974-05-17
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


NVO short term performance overview.The bars show the price performance of NVO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

NVO long term performance overview.The bars show the price performance of NVO in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40

The current stock price of NVO is 56.46 USD. In the past month the price increased by 17.16%. In the past year, price decreased by -59.43%.

NOVO-NORDISK A/S-SPONS ADR / NVO Daily stock chart

NVO Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 45.36 693.36B
JNJ JOHNSON & JOHNSON 17.72 426.69B
AZN ASTRAZENECA PLC-SPONS ADR 18 247.73B
NVS NOVARTIS AG-SPONSORED ADR 14.3 244.98B
MRK MERCK & CO. INC. 10.92 210.11B
PFE PFIZER INC 7.3 140.77B
SNY SANOFI-ADR 11.17 120.68B
BMY BRISTOL-MYERS SQUIBB CO 7.01 96.03B
GSK GSK PLC-SPON ADR 8.8 79.92B
ZTS ZOETIS INC 25.14 69.31B
TAK TAKEDA PHARMACEUTIC-SP ADR 51.69 47.34B
HLN HALEON PLC-ADR 20 43.93B

About NVO

Company Profile

NVO logo image Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Company Info

NOVO-NORDISK A/S-SPONS ADR

Novo Alle 1

Bagsvaerd 2880 DK

CEO: Lars Fruergaard Jorgensen

Employees: 78387

NVO Company Website

NVO Investor Relations

Phone: 4544448888

NOVO-NORDISK A/S-SPONS ADR / NVO FAQ

What is the stock price of NOVO-NORDISK A/S-SPONS ADR today?

The current stock price of NVO is 56.46 USD. The price increased by 0.62% in the last trading session.


What is the ticker symbol for NOVO-NORDISK A/S-SPONS ADR stock?

The exchange symbol of NOVO-NORDISK A/S-SPONS ADR is NVO and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is NVO stock listed?

NVO stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for NOVO-NORDISK A/S-SPONS ADR stock?

31 analysts have analysed NVO and the average price target is 81.61 USD. This implies a price increase of 44.54% is expected in the next year compared to the current price of 56.46. Check the NOVO-NORDISK A/S-SPONS ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NOVO-NORDISK A/S-SPONS ADR worth?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a market capitalization of 250.88B USD. This makes NVO a Mega Cap stock.


How many employees does NOVO-NORDISK A/S-SPONS ADR have?

NOVO-NORDISK A/S-SPONS ADR (NVO) currently has 78387 employees.


What are the support and resistance levels for NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a support level at 55.59 and a resistance level at 56.99. Check the full technical report for a detailed analysis of NVO support and resistance levels.


Is NOVO-NORDISK A/S-SPONS ADR (NVO) expected to grow?

The Revenue of NOVO-NORDISK A/S-SPONS ADR (NVO) is expected to grow by 10.76% in the next year. Check the estimates tab for more information on the NVO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NOVO-NORDISK A/S-SPONS ADR (NVO) stock pay dividends?

NOVO-NORDISK A/S-SPONS ADR (NVO) has a dividend yield of 3.25%. The yearly dividend amount is currently 1.55. Check the full fundamental report for a detailed analysis of NVO dividend history, reliability and sustainability.


When does NOVO-NORDISK A/S-SPONS ADR (NVO) report earnings?

NOVO-NORDISK A/S-SPONS ADR (NVO) will report earnings on 2025-11-05, before the market open.


What is the Price/Earnings (PE) ratio of NOVO-NORDISK A/S-SPONS ADR (NVO)?

The PE ratio for NOVO-NORDISK A/S-SPONS ADR (NVO) is 14.48. This is based on the reported non-GAAP earnings per share of 3.9 and the current share price of 56.46 USD. Check the full fundamental report for a full analysis of the valuation metrics for NVO.


What is the Short Interest ratio of NOVO-NORDISK A/S-SPONS ADR (NVO) stock?

The outstanding short interest for NOVO-NORDISK A/S-SPONS ADR (NVO) is 0.5% of its float. Check the ownership tab for more information on the NVO short interest.


NVO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to NVO. When comparing the yearly performance of all stocks, NVO is a bad performer in the overall market: 95.65% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NVO Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to NVO. While NVO has a great profitability rating, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NVO Financial Highlights

Over the last trailing twelve months NVO reported a non-GAAP Earnings per Share(EPS) of 3.9. The EPS increased by 24.25% compared to the year before.


Industry RankSector Rank
PM (TTM) 35.61%
ROA 23.04%
ROE 66.09%
Debt/Equity 0.52
Chartmill High Growth Momentum
EPS Q2Q%32.74%
Sales Q2Q%12.93%
EPS 1Y (TTM)24.25%
Revenue 1Y (TTM)20.9%

NVO Forecast & Estimates

31 analysts have analysed NVO and the average price target is 81.61 USD. This implies a price increase of 44.54% is expected in the next year compared to the current price of 56.46.

For the next year, analysts expect an EPS growth of 11.47% and a revenue growth 10.76% for NVO


Analysts
Analysts71.61
Price Target81.61 (44.54%)
EPS Next Y11.47%
Revenue Next Year10.76%

NVO Ownership

Ownership
Inst Owners36.28%
Ins OwnersN/A
Short Float %0.5%
Short Ratio1.28